These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 37526372)

  • 41. L-asparaginase-induced reversible posterior leukoencephalopathy syndrome in a child with acute lymphoblastic leukemia.
    Rathi B; Azad RK; Vasudha N; Hissaria P; Sawlani V; Gupta RK
    Pediatr Neurosurg; 2002 Oct; 37(4):203-5. PubMed ID: 12372914
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A Case of ALL Developing Posterior Reversible Encephalopathy Secondary to Hyponatremia.
    Eroglu N; Bahadir A; Erduran E
    J Pediatr Hematol Oncol; 2017 Nov; 39(8):e476-e478. PubMed ID: 28338570
    [TBL] [Abstract][Full Text] [Related]  

  • 43. High incidence of hypertension in children presenting with acute lymphoblastic leukemia.
    Attard-Montalto SP; Saha V; Ng YY; Kingston JE; Eden OB
    Pediatr Hematol Oncol; 1994; 11(5):519-25. PubMed ID: 7826847
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Asparaginase pharmacokinetics after intensive polyethylene glycol-conjugated L-asparaginase therapy for children with relapsed acute lymphoblastic leukemia.
    Hawkins DS; Park JR; Thomson BG; Felgenhauer JL; Holcenberg JS; Panosyan EH; Avramis VI
    Clin Cancer Res; 2004 Aug; 10(16):5335-41. PubMed ID: 15328169
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Survival Outcome of Filipino Children With Acute Lymphoblastic Leukemia Treated With Modified Berlin-Frankfurt-Muenster/Hong Kong Acute Lymphoblastic Leukemia (BFM95/HKALL97) Protocol in a Tertiary General Hospital From January 2005 to December 2009: A Retrospective Cohort Study.
    Dujua AC; Hernandez FG
    J Pediatr Hematol Oncol; 2017 Apr; 39(3):e116-e123. PubMed ID: 28085747
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Bone marrow necrosis and thrombotic complications in childhood acute lymphoblastic leukemia.
    Eguiguren JM; Pui CH
    Med Pediatr Oncol; 1992; 20(1):58-60. PubMed ID: 1727213
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Reversible acute methotrexate leukoencephalopathy: atypical brain MR imaging features.
    Ziereisen F; Dan B; Azzi N; Ferster A; Damry N; Christophe C
    Pediatr Radiol; 2006 Mar; 36(3):205-12. PubMed ID: 16369780
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Low relapse rate in children with acute lymphoblastic leukemia after risk-directed therapy.
    Tzortzatou-Stathopoulou F; Papadopoulou AL; Moschovi M; Botsonis A; Tsangaris GT
    J Pediatr Hematol Oncol; 2001 Dec; 23(9):591-7. PubMed ID: 11902303
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Clinical characteristics and prognosis of seizures in 75 children with acute lymphoblastic leukemia].
    Liu J; Lu AD; Zuo YX; Wu J; Huang ZZ; Jia YP; Ding MM; Zhang LP; Qin J
    Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Oct; 54(5):948-953. PubMed ID: 36241238
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Posterior reversible encephalopathy syndrome in pediatric patients: pathophysiology, diagnosis, and management.
    Ghali MGZ; Davanzo J; Leo M; Rizk E
    Leuk Lymphoma; 2019 Oct; 60(10):2365-2372. PubMed ID: 31556774
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trial.
    Millot F; Suciu S; Philippe N; Benoit Y; Mazingue F; Uyttebroeck A; Lutz P; Mechinaud F; Robert A; Boutard P; Marguerite G; Ferster A; Plouvier E; Rialland X; Behard C; Plantaz D; Dresse MF; Philippet P; Norton L; Thyss A; Dastugue N; Waterkeyn C; Vilmer E; Otten J;
    J Clin Oncol; 2001 Apr; 19(7):1935-42. PubMed ID: 11283125
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Intensified PEG-L-asparaginase and antimetabolite-based therapy for treatment of higher risk precursor-B acute lymphoblastic leukemia: a report from the Children's Oncology Group.
    Salzer WL; Devidas M; Shuster JJ; Wang C; Chauvenet A; Asselin BL; Camitta BM; Kurtzberg J;
    J Pediatr Hematol Oncol; 2007 Jun; 29(6):369-75. PubMed ID: 17551397
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Hepatic sinusoidal obstruction syndrome during maintenance therapy of childhood acute lymphoblastic leukemia is associated with continuous asparaginase therapy and mercaptopurine metabolites.
    Toksvang LN; De Pietri S; Nielsen SN; Nersting J; Albertsen BK; Wehner PS; Rosthøj S; Lähteenmäki PM; Nilsson D; Nystad TA; Grell K; Frandsen TL; Schmiegelow K
    Pediatr Blood Cancer; 2017 Sep; 64(9):. PubMed ID: 28423235
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Intensive oral methotrexate protects against lymphoid marrow relapse in childhood B-precursor acute lymphoblastic leukemia.
    Winick N; Shuster JJ; Bowman WP; Borowitz M; Farrow A; Jacaruso D; Buchanan GR; Kamen BA
    J Clin Oncol; 1996 Oct; 14(10):2803-11. PubMed ID: 8874342
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The utility of performing the initial lumbar puncture on day 8 in remission induction therapy for childhood acute lymphoblastic leukemia: TCCSG L99-15 study.
    Hasegawa D; Manabe A; Ohara A; Kikuchi A; Koh K; Kiyokawa N; Fukushima T; Ishida Y; Saito T; Hanada R; Tsuchida M;
    Pediatr Blood Cancer; 2012 Jan; 58(1):23-30. PubMed ID: 21254378
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: a Pediatric Oncology Group study.
    Amylon MD; Shuster J; Pullen J; Berard C; Link MP; Wharam M; Katz J; Yu A; Laver J; Ravindranath Y; Kurtzberg J; Desai S; Camitta B; Murphy SB
    Leukemia; 1999 Mar; 13(3):335-42. PubMed ID: 10086723
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Thrombosis in childhood acute lymphoblastic leukaemia: epidemiology, aetiology, diagnosis, prevention and treatment.
    Nowak-Göttl U; Kenet G; Mitchell LG
    Best Pract Res Clin Haematol; 2009 Mar; 22(1):103-14. PubMed ID: 19285277
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Allogeneic bone marrow transplantation for childhood acute lymphoblastic leukemia in second remission after intensive primary and relapse therapy according to the BFM- and CoALL-protocols: results of the German Cooperative Study.
    Dopfer R; Henze G; Bender-Götze C; Ebell W; Ehninger G; Friedrich W; Gadner H; Klingebiel T; Peters C; Riehm H
    Blood; 1991 Nov; 78(10):2780-4. PubMed ID: 1824271
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Polyethylene Glycol-conjugated L-asparaginase versus native L-asparaginase in combination with standard agents for children with acute lymphoblastic leukemia in second bone marrow relapse: a Children's Oncology Group Study (POG 8866).
    Kurtzberg J; Asselin B; Bernstein M; Buchanan GR; Pollock BH; Camitta BM
    J Pediatr Hematol Oncol; 2011 Dec; 33(8):610-6. PubMed ID: 22042277
    [TBL] [Abstract][Full Text] [Related]  

  • 60. FDA drug approval summary: pegaspargase (oncaspar) for the first-line treatment of children with acute lymphoblastic leukemia (ALL).
    Dinndorf PA; Gootenberg J; Cohen MH; Keegan P; Pazdur R
    Oncologist; 2007 Aug; 12(8):991-8. PubMed ID: 17766659
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.